Immunic Inc
IMUX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$311.2M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $311.20 Million |
|---|---|
| Enterprise Value | $156.67 Million |
| Earnings per Share | $-6.24 |
| Beta | 1.45 |
| Outstanding Shares | 42,513,839 |
Return
| Return on Equity | -87.45% |
|---|---|
| Return on Assets | -70.09% |
| Return on Invested Capital | -87.73% |
Valuation & Multiples
| P/E Ratio | -1.56 |
|---|---|
| PEG | -5.76 |
| Price to Sales | - |
| Price to Book Ratio | 2.44 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.46 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-1.16
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.06
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 29.94% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.53%▼ 280.53% |
|---|---|
| Total Invested | $6.03M▼ 95.38% |
| Investors Holding | 5▼ 56.00% |
About Immunic Inc
28 employees
CEO: Daniel Vitt
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerati...